Idogen publishes interim report for 1 January – 31 December 2022

Idogen AB's interim report for January to December 2022 is available on the company's website https://idogen.com/en/investors/financial-reports/

Fourth quarter (October-December 2022)

• Other operating income amounted to KSEK 256 (3,335)

• Operating loss was KSEK -11,759 (-13,552)

• Loss for the quarter totaled KSEK -11,465 (-13,529)

• Cash flow from operating activities was KSEK -12,591 (-15,074)

• Loss per share before dilution was SEK -0.16 (-0.61). Loss per share after dilution was SEK -0.16 (-0.61)

• The proposed dividend is SEK 0.00/share (0.00)

Period (January-December 2022)

• Other operating income amounted to KSEK 414 (13,915)

• Operating loss was KSEK -47,972 (-38,965)

• Loss for the quarter totaled KSEK -47,750 (-38,854)

• Cash flow from operating activities was KSEK -50,703 (-40,190)

• Loss per share before dilution was SEK -0.76 (-2.02). Loss per share after dilution was SEK -0.76 (-2.02)

Significant events in the fourth quarter

• First patient is included in Norway.

• Idogen's Idogen sharpens focus on its IDO 8 program, pauses the IDO T and IDO programs and lowers operating expenditure.

• Idogen receives after exercise of warrants 280 KSEK before costs.

• First patient enters Idogen’s hemophilia study under the IDO 8 program.

• EU to disburse the remaining of the Horizon 2020 grant.

• Agneta Edberg elected as new Chairman of Idogen due to changes to the Board of Directors.

• The board of Idogen propose a rights issue at up to 38 MSEK net after cost.

• Idogen invites for an extra shareholder meeting 13 December

Significant events in the period

• Idogen submits an application for clinical trial with IDO 8 to the Norwegian Medicines Agency, NoMA.

• Idogens presented the company’s tolerogenic cell therapy platform at the 5th Antigen-Specific Immune

Tolerance Summit.

• Idogen enters into an agreement with Vator Securities AB regarding the assignment as Certified Adviser from May 15.

• Idogen’s rights issue raise MSEK 41 after issue costs.

• Idogen receives approval from the Swedish Medical Products Agency to start its clinical phase 1/2a study

for IDO 8.

• Idogen’s rights issue raise MSEK 41 after issue costs.

• Idogen receives approval from the Swedish Medical Products Agency to start its clinical phase 1/2a study for IDO 8.

• Idogen strengthens the organization with key competencies for the clinical development phase.

• Idogen brings together scientific advisors at the ISTH 2022 scientific conference in London.

• Idogen receives approval from the Norwegian Medicines Agency, NoMA, for a clinical phase 1/2a study with the IDO 8-program.

• An extraordinary general meeting of shareholders on September 6 elected Joakim Söderström as new

chairman and Niklas Wallet as a new member of the Board of Directors.

• Christina Herder is appointed acting CEO after Anders Karlsson.

Significant events after the end of the period

• New issue gives proceed of net 5.3 MSEK after costs.

• Idogen invited by GJCF to participate in their 3rd Summit for NMOSD Tolerization

• Idogen will pause the clinical trial in the IDO 8 program as the company currently do not have sufficient capital

• No other significant events occurred after the end of the period that affected the results or financial position.

For further information, please contact:

Christina Herder, Acting CEO, Idogen AB

Tel: +46 70 374 71 56

E-mail: christina.herder@idogen.com

Certified Adviser:
Vator Securities AB

The information was submitted for publication, through the agency of the contact persons set out above, on February 24, 2023 at 12:04 CET.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.